 Connection
Hitoshi Irabu to Japan
This is a "connection" page, showing publications Hitoshi Irabu has written about Japan.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.574 |
|
|
|
-
Irabu H, Ohara A, Nakamura A, Narazaki H, Hayashi Y, Yamasaki Y, Iwata N, Ohshima S, Nishiyama S, Nakagishi Y, Fukuhara D, Ishida H, Goto M, Hashimoto K, Yasuoka R, Nozawa T, Miyamae T, Umebayashi H, Mori M, Shimizu M. Validation of the 2019 EULAR/ACR classification criteria and clinical characteristics of childhood-onset Japanese patients with systemic lupus erythematosus. Mod Rheumatol. 2026 Mar 05; 36(2):239-245.
Score: 0.233
-
Irabu H, Shimizu M, Kaneko S, Inoue N, Mizuta M, Tasaki Y, Ohta K, Yachie A, Wada T. Apoptosis inhibitor of macrophage as a biomarker for disease activity in Japanese children with IgA nephropathy and Henoch-Schönlein purpura nephritis. Pediatr Res. 2021 02; 89(3):667-672.
Score: 0.155
-
Miyamae T, Okamoto N, Inoue Y, Kubota T, Ebato T, Irabu H, Kameda H, Kaneko Y, Kubo H, Mitsunaga K, Mori M, Nakajima A, Nishimura K, Ohkubo N, Sato T, Sugita Y, Takanashi S, Tanaka T, Umebayashi H, Yashiro M, Yamanishi S, Fusama M, Hirata S, Kishimoto M, Kohno M, Kojima M, Kojima T, Morinobu A, Sugihara T, Tanaka E, Yajima N, Yanai R, Kawahito Y, Harigai M. Recommendations for the treatment of juvenile idiopathic arthritis with oligoarthritis or polyarthritis from the 2024 update of the Japan College of Rheumatology Clinical Practice Guidelines for the management of rheumatoid arthritis including juvenile idiopathic arthritis with oligoarthritis or polyarthritis - secondary publication. Mod Rheumatol. 2025 Sep 02; 35(5):894-908.
Score: 0.056
-
Kaneko S, Noguchi Y, Hatano M, Shimbo A, Irabu H, Furuno K, Iwata N, Fujimura J, Akamine K, Kobayashi A, Endo T, Morio T, Shimizu M. Clinical Usefulness of T-Cell Receptor Vß Repertoire Analysis for Differentiating Multisystem Inflammatory Syndrome in Japanese Children From Toxic Shock Syndrome and Kawasaki Disease. Pediatr Infect Dis J. 2024 Apr 01; 43(4):e125-e127.
Score: 0.050
-
Yamaguchi Y, Takasawa K, Irabu H, Hiratoko K, Ichigi Y, Hirata K, Tamura Y, Murakoshi M, Yamashita M, Nakatani H, Shimoda M, Ishii T, Udagawa T, Shimizu M, Kanegane H, Morio T. Infliximab treatment for refractory COVID-19-associated multisystem inflammatory syndrome in a Japanese child. J Infect Chemother. 2022 Jun; 28(6):814-818.
Score: 0.044
-
Shimizu M, Irabu H, Kaneda H, Ohta K, Nozu K. Familial focal segmental glomerulosclerosis with PLCE1 mutation in siblings. Pediatr Int. 2019 Jul; 61(7):726-727.
Score: 0.037
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|